Jun 13, 2022 7:00am EDT Algernon Pharmaceuticals Announces Database Lock in Phase 2 Study of IPF and Chronic Cough
May 05, 2022 7:00am EDT Algernon Pharmaceuticals Announces Last Patient Treated in Phase 2 Study of IPF and Chronic Cough
Apr 26, 2022 7:00am EDT Algernon Pharmaceuticals Announces Lead Chronic Kidney Disease Drug Repirinast Reduced Fibrosis by 56% in a Preclinical NASH Study
Feb 23, 2022 7:00am EST Algernon Pharmaceuticals Begins Manufacturing of Repirinast and Launches New Chronic Kidney Disease Research Program
Feb 04, 2022 7:00am EST Algernon Pharmaceuticals Announces Completion of Enrollment in its Phase 2 Study of Ifenprodil for IPF and Chronic Cough
Jan 28, 2022 6:00am EST Algernon Pharmaceuticals Announces Notice of Allowance for Ifenprodil Patent Application for Idiopathic Pulmonary Fibrosis
Jan 24, 2022 7:00am EST Algernon Pharmaceuticals Discloses Novel Salt Patent Strategy as Part of its Psychedelic Drug DMT Intellectual Property
Jan 19, 2022 7:00am EST Algernon Pharmaceuticals Files for Clinical Trial and Ethics Approval for Phase 1 DMT Human Stroke Study
Jan 14, 2022 8:15am EST Algernon Pharmaceuticals Announces Positive Feedback from U.S. FDA for Phase 2b Ifenprodil Chronic Cough Study
